Vir Biotechnology, Inc. (VIR) Q1 2025 Earnings Call

Investor webinar replay

Watch the replay and follow the connected company analysis, news, and investor updates for Vir Biotechnology, Inc..

Watch the replay

Replay transcript excerpt

WEBVTT 00:00:00.031 -- 00:00:02.554 Thank you, and good afternoon. With me today are Dr. 00:00:02.554 -- 00:00:05.598 Marianne DeBacher, our Chief Executive Officer, Dr. 00:00:05.598 -- 00:00:10.344 Mark Eisner, our Chief Medical Officer, Jason O'Byrne, our Chief Financial Officer, and 00:00:10.344 -- 00:00:14.469 Dr. Mika Durink, our Executive Vice President of Oncology, who will be available during 00:00:14.469 -- 00:00:16.772 the Q&A session. 00:00:16.772 -- 00:00:20.477 Before we begin, I would like to remind everyone that some of the statements we are making 00:00:20.477 -- 00:00:24.582 today are forward-looking statements under the securities laws. 00:00:24.582 -- 00:00:28.229 These forward-looking statements involve substantial risk and uncertainties that could 00:00:28.229 -- 00:00:33.015 cause our clinical development programs, future results, performance, or achievements 00:00:33.015 -- 00:00:38.142 to differ significantly from those expressed or implied by such forward-looking statements. 00:00:38.142 -- 00:00:42.487 These risks and uncertainties and risks associated with our business are described in 00:00:42.487 -- 00:00:46.452 the company's reports filed with the Securities and Exchange Commission, including forms 00:00:46.452 -- 00:00:51.579 10-K, 10-Q, and 8-K. I will now turn the call over to our CEO, Dr. 00:00:51.579 -- 00:00:54.722 Marianne DeBacher. Please go ahead. 00:00:54.722 -- 00:00:57.440 Thank you, Rich, and good afternoon, everyone. 00:00:57.440 -- 00:01:02.547 Thank you for joining us for Vier Biotechnology's first quarter 2025 earnings 00:01:02.547 -- 00:01:07.574 call. I'm pleased to share our progress and achievements with you today as we 00:01:07.574 -- 00:01:11.839 continue to execute on our strategic priorities. 00:01:11.839 -- 00:0...